Highlights
- •"Incidental" serous tubal intraepithelial carcinomas (STIC) are uncommon (1/873).
- •Most incidental STICs are discovered during surgery for other epithelial neoplasms.
- •Many incidental STICs are found in women with endometrioid neoplasia.
- •Further studies are needed to clarify the frequency of STIC and its relevance to HGSC.
Abstract
Objective
The purpose of this study was to determine the prevalence of incidentally discovered
serous tubal intraepithelial carcinoma in women without a genetic risk for or history
of high grade serous carcinoma (HGSC) in the gynecologic tract.
Methods
All pathology reports at our institution that included bilateral salpingectomies from
January 2006–December 2011 were examined in women >50 years old in which the entire tube or the distal one-third was examined histologically
with the complete (proximal and distal fallopian tube) or modified (distal one third
of the tube) SEE-FIM protocol. Cases were divided into: Group 1, a history of or known
risk factors (BRCA1 or BRCA2 mutations) for HGSC and Group 2, those without these
attributes for whom a STIC would be unexpected (incidental). Women undergoing unspecified
“risk-reducing” procedures were included in Group 1.
Results
Of 4051 identified total, 2268 had complete examination of the distal fallopian tube
and were age 50 or above. Of these, 1747 were in group 2. Two STICs were identified
(0.1%), one associated with a grade 2 endometrial endometrioid adenocarcinoma and
one with a low-grade ovarian serous carcinoma in the setting of a serous borderline
tumor.
Conclusions
Incidental STICs in women over age 50 are uncommon. However, the significance of lesser
tubal atypias (0.3% in this study), risk of STIC in women with no epithelial pathology
and the risk imposed by coexisting endometrioid neoplasia are unclear and require
further study.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.Gynecol. Oncol. 2016; 141: 260-263
- Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer.J. Pathol. 2001; 195: 451-456
- Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.Am. J. Surg. Pathol. 2007; 31: 161-169
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J. Pathol. 2007; 211: 26-35
- The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.Am. J. Surg. Pathol. 2010; 34: 433-443
- Society of Gynecologic Oncologists Clinical Practice C: prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.Obstet. Gynecol. 2010; 116: 733-743
- Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.Obstet. Gynecol. Clin. N. Am. 2010; 37 (Table of Contents.): 109-133
- Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.N. Engl. J. Med. 2002; 346: 1609-1615
- Salpingectomy as a means to reduce ovarian cancer risk.Cancer Prev. Res. (Phila.). 2015; 8: 342-348
- Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.Cancer. 2015; 121: 2108-2120
- Committee opinion no. 620: salpingectomy for ovarian cancer prevention.Obstet. Gynecol. 2015; 125: 279-281
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am. J. Surg. Pathol. 2006; 30: 230-236
- The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.Gynecol. Oncol. 2014; 134: 486-491
- Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.Mod. Pathol. 2009; 22: 1133-1138
- Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.Am. J. Surg. Pathol. 2014; 38: 729-742
- Incidental serous tubal intraepithelial carcinoma and non-neoplastic conditions of the fallopian tubes in grossly normal adnexa: a Clinicopathologic study of 388 completely embedded cases.Int. J. Gynecol. Pathol. 2015;
- BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?.Obstet. Gynecol. 2005; 106: 1327-1334
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J. Clin. Oncol. 2007; 25: 3985-3990
- Molecular pathogenesis of endometrial and ovarian cancer.Cancer Biomark. 2010; 9: 287-305
- Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.Am. J. Surg. Pathol. 2015; 39: 442-453
- Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube.J. Pathol. 2010; 222: 110-116
- PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer.Mod. Pathol. 2012; 25: 449-455
Article info
Publication history
Published online: May 04, 2017
Accepted:
April 21,
2017
Received in revised form:
April 19,
2017
Received:
January 10,
2017
Footnotes
☆Supported by a grant from the Department of Defense (OC130500 to CPC).
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
